Biopharma | May 08, 2026
Biocon Q4 profit jumps 64%; FY26 revenue crosses Rs. 16,900 crore
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
Clinical guidelines and expert consensus recommend 1.2–1.5 g/kg/day protein intake during therapy to help preserve muscle mass
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Initiative launched with Tata 1mg to benefit 70,000 people across 70 remote villages in Kalahandi region
Digital platform records over 1.34 crore beneficiary registrations with QR-enabled MCH cards and real-time monitoring features
The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities
NEJM study shows strong protection across strains
Hair care & quick commerce shine
The leading cancer hospital urges carrier screening to prevent thalassemia burden
The deal positions MilliporeSigma at the center of commercial manufacturing for three breakthrough gene therapies targeting sickle cell disease, ?-thalassemia, and cerebral adrenoleukodystrophy
Subscribe To Our Newsletter & Stay Updated
